Premium
BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men
Author(s) -
MartínezNava Gabriela Angélica,
Gómez Rocío,
BurgueteGarcía Ana Isabel,
VázquezSalas Ruth Argelia,
VenturaBahena Arianna,
TorresSánchez Luisa
Publication year - 2020
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.23187
Subject(s) - prostate cancer , biology , breast cancer , allele , calcitriol receptor , oncology , medicine , population , genotype , gynecology , cancer , prostate , genetics , gene , environmental health
Prostate cancer (PC) is a polygenic disease with broad differences across ethnicities. BRCA1/2 and VDR have exhibited a featured genetic contribution to PC development in European populations. Nonetheless, its contribution in Latino populations specifically among Mexican men, where 70% of PC cases are detected in advanced stages, is still unknown. The contribution of seven polymorphisms in BRCA 1/2 and VDR genes to PC susceptibility was evaluated in 370 incident PC cases and 759 age‐matched (±5 years) controls belonging to the Mexican population. Based on Gleason score at diagnosis, PC cases were classified as well‐differentiated PC (Gleason <7) and moderate or poorly differentiated PC (Gleason ≥7). Age at diagnosis was used to divided PC cases in earlier (<60 years) and late‐onset PC (≥60 years). Prostate and breast cancer family histories were obtained through interview. Our results provided evidences about the contribution of BRCA1 ‐rs1799966 (OR CC genotype = 2.30; 95% confidence interval [CI] = 1.36‐3.91) to the moderate or poorly differentiated PC risk, independently of the family history of prostate, breast or ovary cancer. Further, VDR ‐rs2238135‐G allele was associated with early‐onset PC (OR G allele = 2.05; 95% CI = 1.06‐3.95), and marginally with moderate or poorly differentiated PC risk. The present study revealed the crucial role of BRCA1 in PC aggressiveness risk, outstanding the gender imbalance regarding the breast cancer risk in women.